Quality of life after sipuleucel-t therapy: Results from a randomized, double-blind study in patients with androgen-dependent prostate cancer

Urology

Volumn 82, Issue 2, 2013, Pages 410-415

  Beer, Tomasz M ^a   Schellhammer, Paul F ^b   Corman, John M ^c   Glodé, L Michael ^d   Hall, Simon J ^e   Whitmore, James B ^f   Frohlich, Mark W ^f   Penson, David F ^g  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Dendreon   (United States)

^g VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

ADULT; AGED; ANDROGEN DEPENDENT PROSTATE CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRIEF FATIGUE INVENTORY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; GLEASON SCORE; GLOBAL RATING OF CHANGE; HUMAN; IMMUNOHISTOCHEMISTRY; LINEAR ANALOG SELF ASSESSMENT SCALE; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SELF EVALUATION; TREATMENT DURATION;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; DOUBLE-BLIND METHOD; FATIGUE; GONADOTROPIN-RELEASING HORMONE; HOT FLASHES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SWEATING; TISSUE EXTRACTS;

EID: 84880866528     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.04.049     Document Type: Article

References (16)

1. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
2. H.W. Herr, and M. O'Sullivan Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy J Urol 163 2000 1743 1746
3. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
4. D.R. Berthold, G.R. Pond, and M. Roessner Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study Clin Cancer Res 14 2008 2763 2767
5. O. Caffo, T. Sava, and E. Comploj Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial BJU Int 108 2011 1825 1832
6. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
7. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
8. C.S. Higano, P.F. Schellhammer, and E.J. Small Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 2009 3670 3679
9. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094
10. T.M. Beer, G.T. Bernstein, and J.M. Corman Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer Clin Cancer Res 17 2011 4558 4567
11. T.R. Mendoza, X.S. Wang, and C.S. Cleeland The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory Cancer 85 1999 1186 1196
12. T.J. Priestman, and M. Baum Evaluation of quality of life in patients receiving treatment for advanced breast cancer Lancet 1 1976 899 900
13. R. Jaeschke, J. Singer, and G.H. Guyatt Measurement of health status. Ascertaining the minimal clinically important difference Control Clin Trials 10 1989 407 415
14. D. Cella, A. Peterman, and S. Hudgens Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane) Cancer 98 2003 822 831
15. S.J. Hall, L. Klotz, and A.J. Pantuck Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer J Urol 186 2011 877 881
16. E.J. Small, C.S. Higano, and P.W. Kantoff Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): results from three randomized phase III trials J Clin Oncol 29 suppl; abstr 4661 2011